New hope for rare nerve disease? early trial tests patisiran
NCT ID NCT05023889
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 16 times
Summary
This early-phase study tests the drug patisiran in 10 adults with a rare disease called wild-type ATTR amyloidosis that causes nerve damage. The goal is to see if patisiran can improve nerve function and quality of life over 24 months. Participants will have regular check-ups and questionnaires to track changes in symptoms like weakness, dizziness, and bowel issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Neuromuscler Center/National Neuromuscular Research Institute
Austin, Texas, 78759, United States
Conditions
Explore the condition pages connected to this study.